Tamarack Advisers’s Boston Scientific BSX Stock Holding History

Tamarack Advisers’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,500	Closed	-$328K	–	28
2017 Q4	$328K	Buy	+1,500	New	+$41.4K	0.18%	27
2017 Q3	–	Sell	-886	Closed	-$55K	–	36
2017 Q2	$55K	Buy	+886	New	+$23.5K	0.03%	32
2016 Q4	–	Sell	-3,500	Closed	-$533K	–	29
2016 Q3	$533K	Buy	+3,500	New	+$83.5K	0.17%	32

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return

Tamarack Advisers's BSX Position: Q2 2017 in Review

Tamarack Advisers sold out of Boston Scientific (BSX) in Q2 2017, closing a stake of 200,000 shares — an estimated $5.31M sold.

Tamarack Advisers first reported a position in BSX in Q4 2016 and held it in 2 quarters. The position peaked at $4.97M in Q1 2017. 558 funds tracked by Wall St. Rank hold BSX as of Q2 2017.

Tamarack Advisers reported no remaining Boston Scientific position as of Q2 2017 after selling out during the quarter.
Tamarack Advisers sold 200,000 Boston Scientific shares in Q2 2017, an estimated $5.31M.
Tamarack Advisers first reported a position in Boston Scientific in Q4 2016 and held it in 2 quarters.
Tamarack Advisers's Boston Scientific position peaked at $4.97M in Q1 2017.
558 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2017.

Based on Tamarack Advisers's 13F filing for Q2 2017, filed 8 Aug 2017.